AstraZeneca COVID drug neutralises Omicron sub-variants in lab study – Reuters
The logo of AstraZeneca is seen on medication packages in a pharmacy in London April 28, 2014. REUTERS/Stefan Wermuth
March 21 (Reuters) – AstraZeneca (AZN.L) said on Monday its antibody-based cocktail to prevent and treat COVID-19 retained neutralising activity against Omicron coronavirus variants, including the highly contagious BA.2 sub-variant, in an independent lab study.
This is the first data looking at the impact of AstraZeneca's Evusheld treatment on "cousins" of the Omicron variant following a recent global spike in cases. The Anglo-Swedish drugmaker said in December that another lab study found that Evusheld retained neutralising activity against Omicron. read more
Data from the latest study by Washington University in the United States showed the therapy reduced the amount of virus detected in samples – viral load – of all tested Omicron sub-variants in mice lungs, AstraZeneca said. The study has yet to be peer reviewed.
Evusheld was tested against the BA.1, BA.1.1, and BA.2 sub-variants of Omicron and it was also shown in the study to limit inflammation in the lungs – a critical symptom in severe COVID-19 infections.
"The findings further support Evusheld as a potential important option to help protect vulnerable patients such as the immunocompromised who could face poor outcomes if they were to become infected with COVID-19," John Perez, head of Late Development, Vaccines & Immune Therapies at AstraZeneca, said.
Last week the World Health Organization said figures showing a global rise in COVID-19 cases could herald a much bigger problem, as the Omicron and BA.2 variants spread amid the easing of restrictions and testing. read more
Evusheld was found to cut the risk of developing symptomatic COVID-19 by 77% in trials, Britain's drug regulator said last week, after approving the therapy for preventing infections in adults with poor immune response. read more
Evusheld has also been shown to save lives and prevent disease progression when given within a week of first symptoms.
While vaccines rely on an intact immune system to develop targeted antibodies and infection-fighting cells, Evusheld contains lab-made antibodies designed to linger in the body for months to contain the virus in case of an infection.
The therapy is currently under a European review. It has already been authorised in the United States.
Our Standards: The Thomson Reuters Trust Principles.
Sign up to our health newsletter to keep up with the latest healthcare trends and pharmaceutical news.
Subscribe to our newsletter to get all the news you need to start your day.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved